Octreotide long-acting repeatable for acromegaly.


Acromegaly remains a therapeutic challenge for the endocrinologist. Among the available therapeutic options, octreotide long-acting repeatable (Sandostatin(®) LAR(®), Novartis) plays a chief role, both as a primary therapy and as an adjuvant treatment after unsuccessful surgery. A plethora of papers and a meta-analysis have demonstrated its efficacy in… (More)
DOI: 10.1586/ecp.12.4


Cite this paper

@article{Cozzi2012OctreotideLR, title={Octreotide long-acting repeatable for acromegaly.}, author={Renato Cozzi and Roberto Attanasio}, journal={Expert review of clinical pharmacology}, year={2012}, volume={5 2}, pages={125-43} }